INTRODUCTION
Variation in the incidence of cancer around the world is, in part, attributed to the significant difference in dietary patterns for fats and phytochemicals such as those in the U.S. compared to Japan. Cancer is the second leading cause of death, while breast cancer is the most common type of this disease among Americans with 1 in 7 women developing breast cancer (1).
In contrast, the incidence and mortality rates of breast cancer in Japanese women are only onethird of those in Americans (2) . Although the rates of breast cancer are much lower in Japan, they have continually climbed in the past 30 years as the diet in Japan has become more westernized similar to that in America.
In the past four decades, Japanese have increased their consumption of animal products and calories from fat while decreased their intake of grains (3) . Meat consumption has increased 7-fold and dairy (which includes conjugated linoleic acids) up to 4-fold in Japan. Since animal products are the principle sources of arachidonic acid (AA), the change in the Japanese diet has resulted in an extraordinary rise in the amount of n-6 polyunsaturated fatty acids (PUFA) thus elevating the ratio of n-6/n-3 PUFA. Regardless of this increase, in 2000 the estimated dietary ratio of 4:1 for n-6/n-3 PUFA in Japan is still considerably lower than the 10:1 to 15:1 range in the American diet (4) . The major dietary sources of n-3 PUFA (eicosapentaenoic acid EPA and docosahexaenoic acid DHA) in the Japanese diet include fish, shellfish, and seaweed.
In addition to the high n-3 PUFA intake, Japanese consume several soy containing food products. Individually, n-3 PUFA or soy components have been implicated in epidemiological (5, 6) , cell culture, and animal studies (7, 8) to play a role in reducing the risk of breast cancer.
However, few studies (only two) have investigated the combined effects of n-3 PUFA and soy genistein on breast cancer (9, 10) . Considering that these food components, n-3 PUFA and soy genistein, are usually consumed as part of the daily Japanese diet, often together in the same meal, they may provide additive or synergistic beneficial effects to protect against chronic diseases.
The most prominent mechanism for the chemopreventive action of n-3 PUFA is their suppressive effect on the production of AA-derived prostanoids, particularly prostaglandin E 2 (PGE 2 ). This prostanoid has been implicated to play a critical role in immune response to cancer cells, inflammation, cancer cell proliferation, differentiation, apoptosis, angiogenesis, and metastasis (7). The n-3 PUFA compete with n-6 PUFA for incorporation into the membrane phospholipids (11) , for the activity of elongases and desaturases involved in the conversion of 18 carbon to 20 and 22 carbon PUFA, and for cyclooxygenase (COX) catalytic sites (12) .
Moreover, some studies proposed that n-3 PUFA down-regulate COX-2 expression (13) by affecting nuclear transcription factors, and altering signal transduction and cell signaling (14) .
Importantly, EPA-derived PGE 3 is much less efficient compared to PGE 2 in inducing COX-2 expression (15) and it is a weaker inflammatory agent (16) .
Genistein was reported to lower PGE 2 production in mesangial cells and macrophages (17, 18) . Genistein may lower PGE 2 by blocking the mitogen-activated protein kinase signaling cascades (19) that activate the transcription of the COX-2 gene, or as a potent peroxisome proliferator activated receptor gamma (PPARγ) ligand increasing peroxisome proliferator response element (PPRE) transcriptional activity at concentrations of ≥ 5 µmol/L (20) . Genistein has also been demonstrated to activate PPRE transcriptional activity through PPARα in HeoG2 human hepatoma cells (21) . Activation of PPRE has been associated with the inhibition of nuclear factor kappa B (NFκB) activity and a consequential reduction in COX-2 expression (22).
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In addition, genistein can act via a PPARγ-independent mechanism to inhibit NFκB activation and the binding of NFκB to DNA (23, 24) . Therefore, genistein can potentially reduce the level of COX-2 protein and PGE 2 production by altering NFκB signaling as demonstrated in macrophages (18) .
In the present investigation, n-3 PUFA and genistein were hypothesized to synergistically suppress AA-derived PGE 2 production and COX-2 expression in MDA-MB-231 cancer cells to decrease cell invasiveness. MDA-MB-231 is a highly invasive cancer cell line that overexpresses COX-2. The effects of n-6 PUFA compared to n-3 PUFA alone and in combination with genistein were studied on PGE 2 production and COX-2 expression. Levels of NFκB and PPARγ, the nuclear factors involved in the transcription of COX-2 gene, and the invasive capacity of the cells were also examined. Statistical analyses. Data were analyzed by either a Student's t-test or one-way ANOVA. For ANOVA analysis, where significant differences were found, a Tukey's multiple comparison test was performed at a probability of P < 0.05 (SAS software, SAS Institute Inc., Cary, NC). All data are presented as means ± SD or as standardized differences calculated from the difference between values of treatment and control divided by the pooled SEM. Importantly, genistein alone did not affect the level of COX-2 mRNA (as also shown in Figure   3 ) and hence the suppression observed in the AA plus genistein treatment was an effect exclusive to the combination of these compounds. This finding suggests that genistein has a protective effect by reducing the action of AA on COX-2 at the transcription level to the same extent achieved by LC n-3 PUFA treatments. To further study how PUFA and genistein impact the mechanism involved in the molecular control of the COX-2 gene expression, the effects of these dietary components on PPARγ and NFκB genes expression were also examined. Genistein treatment alone at the concentration used had no significant effect on mRNA levels for both PPARγ (Figure 4 This finding may suggest that physiological concentrations of n-3 PUFA and genistein maintained for long duration are effective to sustain COX-2 gene suppression through their actions on PPARγ and NFκB.
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DISCUSSION
The chemopreventive capacity of LC n-3 PUFA has been documented in the past two decades. Evidence suggests that LC n-3 PUFA antagonize AA-derived prostanoid formation through mechanisms involving substrate replacement, enzyme competition, signal transduction, and modulation of gene expression (7, 27 further lowered. Hence, our data provide evidence for an additive effect of DHA plus genistein in suppressing the endogenous production of PGE 2 in MDA-MB-231 cells.
In our study, treatments with LC n-3 PUFA reduced COX-2 mRNA level independent of the addition of genistein. This is not surprising since both DHA and EPA were reported to lower COX-2 expression by blocking the toll-like receptor-mediated pathway thereby inhibiting NFκB activation (35) . Treatments with AA, on the other hand, showed reduction in COX-2 mRNA level only when combined with genistein. We observed that the reduction in COX-2 expression coincided with increased PPARγ expression and lowered NFκB expression. Our observation is consistent with another study in which cervical cancer cells treated with PPARγ ligand had upregulated PPARγ expression, suppressed binding activity of NFκB, and reduced expression of COX-2 gene (36) . Genistein has been shown to activate PPARγ (20) , and to inactivate NFκB or prevent NFκB binding to DNA (37) . We propose that LC n-3 PUFA act complementarily with genistein to increase the transcription of PPARγ and decrease the transcription of NFκB to suppress the expression of COX-2. Since NFκB has two binding sites on the COX-2 promoter (37), it is feasible that the addition of genistein to cells enriched with AA led to inactivation of NFκB, mediated through higher expression of PPARγ or by direct effect on NFκB, to reduce the transcription of the COX-2 gene. When genistein was in combination with EPA or DHA, genistein did not enhance the suppression of COX-2 gene expression but worked through another mechanism (likely to also involve PPARγ) to lower PGE 2 production and the invasive phenotype of the cancer cells. It is also noteworthy that activation of PPRE may directly induce the COX-2 gene promoter (38) , however, since there are two sites for NFκB and only one for PPRE which is located much further upstream from the start site of transcription compared to the NFκB sites, it seems that suppression of NFκB may override activation of PPRE.
From our investigation, the chemopreventive effect of LC n-3 PUFA and genistein may be three-fold. First, we observed that treatment with DHA and genistein reduced the synthesis of PGE 2 , a compound implicated in carcinogenesis and inflammation. Second, EPA and DHA lowered the expression of COX-2 and NFκB to decrease the production of PGE 2 . The lowering effect of EPA and DHA on NFκB transcription in the same breast cancer cells was observed in our laboratory with stearidonic acid (18:4n-3) enrichment (25) . Third, genistein blocked the actions of AA on PGE 2 , cell invasiveness, and COX-2 and NFκB expression.
Simultaneous targeting of COX-2 and PPARγ has been suggested as a powerful mechanism to lower the risk of cancer (39) . We observed that LC n-3 PUFA effectively downregulated PGE 2 production, along with DHA being a potential ligand for RXRα (40) and genistein as a PPARγ ligand, they appear to work together to activate the PPRE transsuppression of pro-inflammatory and pro-carcinogenic genes (e.g. NFκB). In breast cancer cells, including the MDA-MB-231 cell line used in our study, treatment with 15-d-PGJ 2 was reported to induce apoptosis (41) and inhibit proliferation (42) . Therefore, our study is the first to evoke a complementary nature of DHA and genistein that would alter or decrease the flux through prostanoid pathways.
Intakes of foods containing LC n-3 PUFA and genistein may be an effective strategy to reduce the risk of breast cancer by downregulating the production of pro-inflammatory cytokines and invasiveness of cancer cells. Importantly, this study found that in AA-treated human cancer cells, genistein effectively lowered PGE 2 as well as the expression of COX-2 and NFκB, suggesting a potential cancer protective effect of soy products in Japanese populations that recently began consume increasing amount of dietary n-6 PUFA (arachidonic acid). is calculated by a two-tailed Student's t-test (P < 0.05).
Fig. 5.
In the present study, the combination of DHA and genistein antagonized the effect of AA on prostanoid production. Genistein and DHA can inhibit the activation of NFκB by
PPARγ-dependent and -independent mechanisms (20, 23, 24, 35, 40) , leading to downregulation of the COX-2 gene, PGE 2 production, and synthesis of NFκB-regulated proinflammatory cytokines (18, 22, 43) . DHA and genistein can also suppress the production of PGE 2 by altering the flux through the COX-2 enzyme (11, 12) . Additionally, genistein can potentially interfere with signal transduction involved in the elevation of cAMP levels (17, 44) , hence it prevents the inducing effect of PGE 2 on COX-2 gene transcription.
